[go: up one dir, main page]

UY35848A - Tienopirimidinas - Google Patents

Tienopirimidinas

Info

Publication number
UY35848A
UY35848A UY0001035848A UY35848A UY35848A UY 35848 A UY35848 A UY 35848A UY 0001035848 A UY0001035848 A UY 0001035848A UY 35848 A UY35848 A UY 35848A UY 35848 A UY35848 A UY 35848A
Authority
UY
Uruguay
Prior art keywords
compounds
preparing
tienopirimidins
angiogenesis
prophylaxis
Prior art date
Application number
UY0001035848A
Other languages
English (en)
Inventor
Behenna Douglas Carl
Cho-Schultz Sujin
Cheng Hengmiao
Kath John Charles
Nagata Asako
Nair Sajiv Krishnan
Planken Simon Paul
Johnson Jr Theodore Otto
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY35848A publication Critical patent/UY35848A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de tienopirimidina sustituidos de la fórmula general (I) que se describen y definen en la presente,métodos de preparación de dichos compuestos, compuestos intermediarios de utilidad para preparar dichos compuestos,composiciones y combinaciones farmacéuticas que comprenden dichos compuestos y el uso de dichos compuestos en la elaboración de una composición farmacéutica para el tratamien to o la profilaxis de una enfermedad, en particular de un trastorno hiperproliferativo y/o de angiogénesis, como agente único o en combinación con otros ingredientes activos.
UY0001035848A 2013-11-20 2014-11-19 Tienopirimidinas UY35848A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13193665 2013-11-20
EP14174731 2014-06-27

Publications (1)

Publication Number Publication Date
UY35848A true UY35848A (es) 2015-06-30

Family

ID=52000798

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035848A UY35848A (es) 2013-11-20 2014-11-19 Tienopirimidinas

Country Status (22)

Country Link
US (1) US20160297833A1 (es)
EP (1) EP3071577A1 (es)
JP (1) JP2016539113A (es)
KR (1) KR20160086404A (es)
CN (1) CN106061980A (es)
AP (1) AP2016009225A0 (es)
AU (1) AU2014352066A1 (es)
BR (1) BR112016011472A2 (es)
CA (1) CA2930873A1 (es)
CL (1) CL2016001218A1 (es)
CR (1) CR20160235A (es)
CU (1) CU20160072A7 (es)
DO (1) DOP2016000118A (es)
EA (1) EA201600398A1 (es)
IL (1) IL245404A0 (es)
MX (1) MX2016006631A (es)
PE (1) PE20160593A1 (es)
PH (1) PH12016500931A1 (es)
TN (1) TN2016000194A1 (es)
TW (1) TW201605867A (es)
UY (1) UY35848A (es)
WO (1) WO2015074986A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
CN108602814A (zh) 2015-10-29 2018-09-28 效应治疗股份有限公司 抑制mnk1和mnk2的吡咯并-、吡唑并-、咪唑并-嘧啶和吡啶化合物
BR112018008714A2 (pt) * 2015-10-29 2018-10-30 Effector Therapeutics Inc inibidores de isoindolina, azaisoindolina, dihidroindenona e dihidroazaindenona da mnk1 e mnk2
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
EP3571206A1 (en) 2017-01-20 2019-11-27 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
MX394700B (es) 2017-02-14 2025-03-24 Effector Therapeutics Inc Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
KR20210102211A (ko) 2018-10-24 2021-08-19 이펙터 테라퓨틱스, 인크. Mnk 억제제의 결정질 형태
CN110981903A (zh) * 2019-11-28 2020-04-10 南京正济医药研究有限公司 一种艾日布林中间体化合物提高光学纯度的精制方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088138A1 (en) * 2001-04-30 2002-11-07 Bayer Corporation Novel 4-amino-5,6-substituted thiopheno[2,3-d]pyrimidines
WO2003059913A1 (en) * 2002-01-10 2003-07-24 Bayer Healthcare Ag Roh-kinase inhibitors
US7238701B2 (en) * 2003-07-24 2007-07-03 Bayer Pharmaceuticals Corporation Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
EP1799653B1 (en) * 2004-08-20 2013-03-20 Bayer Intellectual Property GmbH Condensed thienopyrimidine derivatives for the treatment of cancer
UY29161A1 (es) * 2004-10-15 2006-04-28 Bayer Pharmaceuticals Corp Nuevos heterociclos
US20100143341A1 (en) * 2005-06-22 2010-06-10 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
WO2007059905A2 (en) * 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
US8754079B2 (en) * 2010-02-26 2014-06-17 Boehringer Ingelheim International Gmbh Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
AU2013207972B2 (en) * 2012-01-10 2017-06-15 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
CA2873967A1 (en) * 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
EP2852593A1 (en) * 2012-05-21 2015-04-01 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidines
CA2873975A1 (en) * 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Thienopyrimidines
EP2951187A1 (en) * 2013-02-01 2015-12-09 Bayer Pharma Aktiengesellschaft Substituted thienopyrimidines and pharmaceutical use thereof
AP2016009025A0 (en) * 2013-07-08 2016-02-29 Bayer Pharma AG Substituted pyrazolo-pyridinamines

Also Published As

Publication number Publication date
BR112016011472A2 (pt) 2017-09-26
CL2016001218A1 (es) 2016-12-16
CR20160235A (es) 2016-07-20
EP3071577A1 (en) 2016-09-28
TN2016000194A1 (en) 2017-10-06
DOP2016000118A (es) 2016-06-30
US20160297833A1 (en) 2016-10-13
AP2016009225A0 (en) 2016-05-31
JP2016539113A (ja) 2016-12-15
EA201600398A1 (ru) 2016-10-31
CN106061980A (zh) 2016-10-26
PE20160593A1 (es) 2016-07-13
AU2014352066A1 (en) 2016-05-26
CA2930873A1 (en) 2015-05-28
TW201605867A (zh) 2016-02-16
IL245404A0 (en) 2016-06-30
CU20160072A7 (es) 2016-10-28
MX2016006631A (es) 2016-08-17
PH12016500931A1 (en) 2016-06-27
WO2015074986A1 (en) 2015-05-28
KR20160086404A (ko) 2016-07-19

Similar Documents

Publication Publication Date Title
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
UY33598A (es) Imidazopiridazinas sustituidas
ECSP17007538A (es) 2-(morfolin-4-il)-1,7-naftiridinas
MX2015011316A (es) Imidazopiridazinas sustituidas.
UY35848A (es) Tienopirimidinas
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
MX2014002697A (es) Imidazopiridazinas sustituidas con amino.
NI201600006A (es) Pirazolo-piridinaminas sustituidas
CR20160433A (es) Nuevos compuestos
NI201700078A (es) Pirazolpiridinaminas
UY37577A (es) Dihidroimidazopiridindionas sustituidas
UY37444A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso
UY36983A (es) Pirazolopiridinaminas sustituidas
UY34630A (es) Imidazopiridazinas sustituidas con amino
UY37032A (es) Compuestos de heteroarilbenzimidazol

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211221